Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survival Benefits of Statins in Breast Cancer Patients With Abnormal Lipid Metabolism
NCT03971019Phase 3Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of simvastatin and atorvastatin in breast cancer (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
simvastatinatorvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03971019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971019.